A Canadian licensed producer (LP) will begin raising capital in the public market after announcing an initial public offering (IPO).
Tilray, a private federally sanctioned cannabis producer in Canada since 2014, announced it will seek a Class 2 common stock listing on the NASDAQ Global Select Market with the ticker symbol “TLRY.”
Tilray has not determined how many shares will be offered in the IPO or the price range for the offering.
Find out what experts say about profiting from the cannabis market in 2021!
Read our FREE 2021 cannabis outlook report!
“Cowen and BMO Capital Markets will jointly act as book runners for the proposed IPO,” Tilray revealed, with the two banking institutions splitting the duties of running the IPO between two countries. Cowen will lead the US launch and BMO the one in Canada.
The company indicated it has filed for a preliminary prospectus for a proposed IPO in Canada with the securities regulatory authorities of all Canadian provinces other than Quebec. However, Tilray doesn’t plan to list on any Canadian stock exchange.
One indicator as to why Tilray is electing to raise capital in the US rather than on a Canadian exchange relates to the limitations TMX Group has placed around possession and/or connection to US cannabis assets.
While Tilray sells medical cannabis to patients in Canada exclusively, Privateer Holdings, the parent company of the cannabis producer, also holds Marley Natural, a cannabis brand currently selling products in legal states California and Oregon. The brand offers cannabis oil cartridges, pre-rolls and whole flower for consumers.
The private producer will join fellow Canadian LP Cronos Group (NASDAQ:CRON,TSX:CRON) as one of the only cannabis companies on the NASDAQ. This year, Canopy Growth (NYSE:CGC,TSX:WEED) became the first cannabis company to list publicly on the New York Stock Exchange.
On Tuesday (June 19), Sandoz Canada, a drug maker, confirmed a partnership with Tilray to begin developing new product dosage forms and delivery systems. Tilray will begin offering eight of its existing cannabis products in partnership with Sandoz, meaning the pharmaceutical firm’s name and logo will be visible on the products.
The collaboration will also invest in research studies to “advance the science in a variety of medical conditions.”
“Both Sandoz and Tilray recognize that there continues to be an unmet need in access to, and dosing of, medical cannabis products,” said Michel Robidoux, president and general manager of Sandoz Canada.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Find out what experts say about profiting from the cannabis market in 2021!
Read our FREE 2021 cannabis outlook report!
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
March 04 | 2021
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
<p>The polyphenols in olives have demonstrated the ability (Alagna et al. BMC Plant Biology 2012, 12:162) to protect LDL particles from oxidative damage and to maintain normal blood HDL-cholesterol concentrations, required to maintain normal hemostatic function. These polyphenols have also demonstrated positive effects on learning and reducing memory deficits found in ageing (such as those related to the overproduction of amyloid-beta peptide). In addition, they can impact gut microbial balance by promoting growth of bacteria, influencing lipid metabolism and inhibition of pathogenic bacteria, as well as increase bone density.</p>
<p>BioHarvest’s olive cells-based product will contain verbascoside, which is an ingredient with potent activity from the olive tree. This is a major differentiator of our product as most olive extracts are based only on hydroxytyrosol, typical of the inedible vegetation waters from the tree and of aged extra-virgin olive oils. </p>
<p> “<i>We are very proud to have achieved this milestone</i>,” said Dr. Yochi Hagay, CTO of the Company and added, <i>“Our Nutraceuticals development program includes new products with active ingredients that have scientifically demonstrated a positive impact on a person’s wellbeing. Our olive-based Nutraceutical contains a matrix of active components with special antioxidant activities and unlike other products (which use the typical solvent extraction technique), is based on our proprietary BioFarming technology which keeps the original natural molecular conformation of the components and hence delivers optimal bioavailability.” </i></p>
<p> “<i>This is yet one more achievement from our talented scientists. It provides further evidence of the vast potential of our BioFarming technology which can produce compounds in their natural structure and maximize the health of consumers. We expect to commercialize this olive based product alongside our current flagship VINIA® product in 2022 to create a portfolio of superfruits and Nutraceuticals with unprecedented benefits and sales growth potential in the $53 Billion dietary supplement market in the US (2020 Persistence Market Research),” </i>said Ilan Sobel, the CEO of the Company.</p>
<p><b>About <a href="https://investingnews.com/company-profiles/bioharvest-sciences-cse:bhsc/">BioHarvest Sciences Inc.</a></b></p>
<p>Based in Vancouver BC, <a href="https://investingnews.com/company-profiles/bioharvest-sciences-cse:bhsc/">BioHarvest Sciences Inc.</a> is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company’s technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by <a href="https://investingnews.com/company-profiles/bioharvest-sciences-cse:bhsc/">BioHarvest Sciences Inc.</a> The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the cannabis plant, and building adequate production capacity, <a href="https://investingnews.com/company-profiles/bioharvest-sciences-cse:bhsc/">BioHarvest Sciences Inc.</a>‘s objective is to also become a leading supplier of cannabis for both medicinal and legal recreational purposes.</p>
<p>For more information visit: <a href="https://www.newsfilecorp.com/redirect/QGVOF83LG" rel="noopener noreferrer" target="_blank">www.bioharvest.com</a>.</p>
<p><b><a href="https://investingnews.com/company-profiles/bioharvest-sciences-cse:bhsc/">BioHarvest Sciences Inc.</a></b><br/>Ilan Sobel, Chief Executive Officer</p>
<p><b>For further information, please contact:</b><br/>Dave Ryan, VP Investor Relations & Director<br/>Phone: 1 (604) 622-1186<br/>Email: <a href="mailto:dave@bioharvest.com" rel="noopener noreferrer" target="_blank">dave@bioharvest.com</a><u> </u></p>
<p><a href="https://www.newsfilecorp.com/redirect/px2qHw5a4" rel="nofollow noopener noreferrer" target="_blank">Twitter</a><br/><a href="https://www.newsfilecorp.com/redirect/Yv7mhpMWe" rel="nofollow noopener noreferrer" target="_blank">Facebook</a><br/><a href="https://www.newsfilecorp.com/redirect/0z27srkw1" rel="nofollow noopener noreferrer" target="_blank">LinkedIn</a><br/><a href="https://www.newsfilecorp.com/redirect/RXLzCAOWP" rel="nofollow noopener noreferrer" target="_blank">YouTube</a></p>
<p><b>Forward-Looking Statements </b></p>
<p><i>Information set forth in this news release includes might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, there is no assurance that we will achieve our objective of making our products available in multiple markets and exposing our technology to different verticals. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. The success of the Company in its olive-base’s development program is not an assurance that the Company will be able to commence commercial production when anticipated or at all. </i></p>
<p><i>All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. </i></p>
<p><b>Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.</b></p>
<p id="corporateNewsLogoContainer"><img alt="Corporate Logo" class="lazy" data-src="https://orders.newsfilecorp.com/files/6168/76078_1a149d938406e9ee_logo.jpg" data-srcset="" id="corporateNewsLogo" src="https://orders.newsfilecorp.com/files/6168/76078_1a149d938406e9ee_logo.jpg" srcset=""/></p>
<p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://www.newsfilecorp.com/redirect/mZq3uRM5Z" rel="noopener noreferrer" target="_blank">https://www.newsfilecorp.com/release/76078</a></p>
<p><img alt="" class="lazy" data-src="https://www.newsfilecorp.com/newsinfo/76078/310" data-srcset="" src="https://www.newsfilecorp.com/newsinfo/76078/310" srcset=""/></p>
</div>
<p>News Provided by Newsfile via QuoteMedia</p>
<p></p><div class="stock-information sidebar-block">
<div class="title">Request an Investor Kit: <h3>BioHarvest Sciences</h3></div>
<form action="https://investingnews.com" id="subscribe_per_category" method="POST">
<div class="form-column left">
<input name="profiles_only" type="hidden" value="yes"/><input name="subscription_form" type="hidden" value="yes"/><input name="subscribe_company_profile_form" type="hidden" value="1"/><input name="source" type="hidden" value="https://investingnews.com/news/biotech-investing/bioharvest-sciences-inc.unveils-the-unique-polyphenolic-content-of-its-upcoming-olive-based-nutraceutical/"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="form_name" type="hidden" value="subscribe_cprofile_use_posts"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="cprofiles[]" type="hidden" value="Tzo4OiJzdGRDbGFzcyI6NDp7czoyOiJpZCI7czozNjoiYWJhZmU3MTgtNmUzMC1hYTc0LWVhNjctNWQyNzRhNGY2NjQ1IjtzOjQ6Im5hbWUiO3M6MTk6IkJpb0hhcnZlc3QgU2NpZW5jZXMiO3M6NDoid3BpZCI7czo5OiIxMDE1MTUyMTYiO3M6MzoidXJsIjtzOjA6IiI7fQ=="/><input class="form-control" id="FirstName" name="first_name" placeholder="First Name" required="" type="text" value=""/><input class="form-control" id="LastName" name="last_name" placeholder="Last Name" required="" type="text" value=""/><input class="form-control" id="email" name="email" placeholder="Email" required="" type="email" value=""/><input class="form-control" id="phone" name="user_phone" pattern="[\+\s0-9]{3,15}" placeholder="Phone" title="Telephone number. Only digits and space signs are allowed" type="tel" value=""/></div>
<div class="form-column right">
<div class="extra-input">
<input id="AccreditedInvestor" name="accredited_investor" type="checkbox"/><label class="checkbox-label" for="AccreditedInvestor">
Include me in the <b>Accredited Investor</b> email list
<span class="help">
<i aria-hidden="true" class="fa fa-question-circle"></i>
<div class="help-box bigger">
Some investment opportunities are limited to accredited investors. Whether you are an accredited investor or not depends on where you live and other criteria. For full details go to https://investingnews.com/accredited-investor-definition/ or search for "accredited investor" in the search bar above.
</div>
</span>
</label>
</div>
<div class="more">
<input class="btn btn-primary" type="submit" value="Get More information"/></div>
<p class="legend">By completing this form, you are giving consent to receive communication from BioHarvest Sciences using the contact information you provide. And remember you can unsubscribe at any time.</p>
</div>
</form>
</div>
Keep reading...
Show less
Regulatory approvals place Numinus lab at the forefront of global psychedelics research
March 04 | 2021
Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of psychedelic compounds
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), has received new amendments under Canada’s Controlled Drugs and Substances Act that enhance the Company’s ability to lead psychedelics research and support the global psychedelics sector.
<div id="DivAssetPlaceHolder1">
<p> <a href="https://mma.prnewswire.com/media/1449398/Numinus_Wellness_Inc__Regulatory_approvals_place_Numinus_lab_at.html" rel="nofollow noopener noreferrer" target="_blank"> <img alt="Numinus Wellness Inc. (CNW Group/Numinus Wellness Inc.)" class="lazy" data-src="https://mma.prnewswire.com/media/1449398/Numinus_Wellness_Inc__Regulatory_approvals_place_Numinus_lab_at.jpg" data-srcset="" src="https://mma.prnewswire.com/media/1449398/Numinus_Wellness_Inc__Regulatory_approvals_place_Numinus_lab_at.jpg" srcset="" title="Numinus Wellness Inc. (CNW Group/Numinus Wellness Inc.)"/></a> </p>
</div>
<p> <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> Bioscience, which operates a state-of-the-art research lab in <span> British Columbia, Canada </span> , recently received amendments to its federal licence to allow the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelics including – for the first time – Ketamine and Lysergic acid diethylamide (LSD). The amendment also supports <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> Bioscience’s role in these activities related to Mescaline, N,N-Dimethyltryptamine (DMT), N-Methyl-3,4, methylenedioxyamphetamine (MDMA), Psilocin and Psilocybin. </p>
<p> “These amendments are not just exciting for <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> and our researchers, but also for our partners, clients and potentially academic collaborators in the psychedelics space,” said <span> Sharan Sidhu </span> , Science Officer and General Manager for <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> Bioscience. “The amendments dramatically expand the work we can do with a far larger group of psychedelics, and open up market-leading and revenue-generating opportunities for <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> in R&D, psychedelic formulations, research and analysis. Moreover, we can now develop and implement standardized psychedelics testing on top of our existing high throughput capabilities, and formulate and produce psychedelic compounds in finished packaged products for clinical trials, clinical use under exemption, and export.” </p>
<p> Among other valued-added services, the amendments enable <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> Bioscience to pursue formulation and stability studies to assemble finished products for all approved psychedelics. </p>
<p> Previously, <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> Bioscience conducted R&D and analytical testing on <i> Psilocybe </i> mushrooms. New amendments allow <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> Bioscience to conduct all activities related to possession, production, sale, export, delivery and assembly for <i> Psilocybe </i> mushroom fruiting bodies, both whole ground and extracted, to stakeholders that possess a Section 56 exemption. </p>
<p> In addition, the new amendments allow <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> Bioscience to increase the amount of Psilocin and Psilocybin produced at the lab from 505 grams to 1000 grams annually, consisting of 750 grams of Psilocybin and 250 grams of Psilocin. Health <span> Canada </span> has also acknowledged that the Company can continue to supply verified and validated <i> Psilocybe </i> mushroom spores and tissue culture that do not contain controlled substances to other licensed dealers and can be listed as a supplier. In coming quarters, <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> Bioscience will prepare to offer the expanded suite of psychedelic products and services allowed by recent amendments. </p>
<p> “The approvals announced today mark a key milestone in advancing the integrated services model we are building to research and ultimately deliver quality therapies to people who may benefit, across the spectrum of mental health disorders,” said <span> Payton Nyquvest </span> , CEO, <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a>. “We know that currently available treatments for mental health disorders are often ineffective and can lead to major unwanted side effects. To date, clinical trials for professionally supervised psychedelic-assisted psychotherapies have shown safety and efficacy, with fewer and less severe side effects than conventional medicines.” </p>
<p> As the first public entity to legally cultivate and extract <i> Psilocybe </i> mushrooms under its dealers’ license, <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> Bioscience is already a research leader in the psychedelics industry. The BC lab is licensed by Health Canada. </p>
<p> <b> Note </b> </p>
<p> The safety and efficacy of psychedelic-assisted psychotherapy is currently under investigation. It has not yet been approved by Health Canada or the U.S. FDA, does not work for everyone, and carries risks even in therapeutic settings. These statements are no guarantee of future Health Canada or FDA approval or availability of psychedelic-assisted psychotherapy. These statements necessarily involve known and unknown risks and uncertainties, which may cause actual outcomes to differ materially from projections. </p>
<p> <b> About <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> </b> </p>
<p> <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus Wellness Inc.</a> (<a href="https://investingnews.com/stock-information/?symbol=NUMI:CA">TSXV:NUMI</a>) is a health care and research company creating psychedelic-centred solutions to treat mental illness, substance abuse and trauma. </p>
<p> <b> <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> Health </b> delivers treatments through clinics and virtual services, with clinics in <span> Vancouver </span> and <span> Montreal </span> . </p>
<p> <b> <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> R&D </b> develops clinical and therapeutic protocols to use in treatments, in collaboration with research partners and regulators. </p>
<p> <b> <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus</a> Bioscience </b> develops formulations and methods for a safe supply, using Health Canada licences, scientific expertise and cutting-edge technology. </p>
<p> Learn more at <u> <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/" rel="nofollow noopener noreferrer" target="_blank"> numinus.ca </a> </u> , and follow us on <u> <a href="https://c212.net/c/link/?t=0&l=en&o=3086229-1&h=3842953927&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2927533-1%26h%3D3339836064%26u%3Dhttps%253A%252F%252Fwww.facebook.com%252FNuminusInc%26a%3DFacebook&a=Facebook" rel="nofollow noopener noreferrer" target="_blank"> Facebook </a> </u> , <u> <a href="https://c212.net/c/link/?t=0&l=en&o=3086229-1&h=2440185876&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2927533-1%26h%3D808559263%26u%3Dhttps%253A%252F%252Ftwitter.com%252FNuminusInc%26a%3DTwitter&a=Twitter" rel="nofollow noopener noreferrer" target="_blank"> Twitter </a> </u> , and <u> <a href="https://c212.net/c/link/?t=0&l=en&o=3086229-1&h=1306849520&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2927533-1%26h%3D1703748714%26u%3Dhttps%253A%252F%252Fwww.instagram.com%252Fnuminusinc%252F%26a%3DInstagram&a=Instagram" rel="nofollow noopener noreferrer" target="_blank"> Instagram </a> </u> . </p>
<p> <b> Forward Looking Statements </b> </p>
<p> <i> This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licences and any inability to obtain all necessary governmental approvals licences and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers; the development and implementation of medical protocols and treatment standard operating procedures for the use of psychedelic therapies; the Company’s goals to develop and implement partnerships with research organizations and other key players in the integrative mental health industry; the Company’s ability to successfully withstand the economic impact of COVID-19; the medical benefits, safety, efficacy, dosing and social acceptance of psychedelics; the approval and/or success of compassionate access clinical trials; the cultivation and harvest of psilocybe mushrooms; and the availability of trained personnel and medical professionals. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law. </i> </p>
<div id="DivAssetPlaceHolder2"> </div>
<p> SOURCE <a href="https://investingnews.com/company-profiles/numinus-tsxv:numi/">Numinus Wellness Inc.</a> </p>
<p> <img alt="" class="lazy" data-src="https://rt.newswire.ca/rt.gif?NewsItemId=C2321&Transmission_Id=202103040800CANADANWCANADAPR_C2321&DateId=20210304" data-srcset="" src="https://rt.newswire.ca/rt.gif?NewsItemId=C2321&Transmission_Id=202103040800CANADANWCANADAPR_C2321&DateId=20210304" srcset=""/></p>
<p> <img alt="Cision" class="lazy" data-src="https://c212.net/c/img/favicon.png?sn=C2321&sd=2021-03-04" data-srcset="" height="12" src="https://c212.net/c/img/favicon.png?sn=C2321&sd=2021-03-04" srcset="" title="Cision" width="12"/> View original content to download multimedia: <a href="http://www.newswire.ca/en/releases/archive/March2021/04/c2321.html" rel="noopener noreferrer" target="_blank"> http://www.newswire.ca/en/releases/archive/March2021/04/c2321.html </a> </p>
</div>
</div>
<p>News Provided by Canada Newswire via QuoteMedia</p>
<p></p><div class="stock-information sidebar-block">
<div class="title">Request an Investor Kit: <h3>Numinus</h3></div>
<form action="https://investingnews.com" id="subscribe_per_category" method="POST">
<div class="form-column left">
<input name="profiles_only" type="hidden" value="yes"/><input name="subscription_form" type="hidden" value="yes"/><input name="subscribe_company_profile_form" type="hidden" value="1"/><input name="source" type="hidden" value="https://investingnews.com/news/cannabis-investing/regulatory-approvals-place-numinus-lab-at-the-forefront-of-global-psychedelics-research/"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="form_name" type="hidden" value="subscribe_cprofile_use_posts"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="cprofiles[]" type="hidden" value="Tzo4OiJzdGRDbGFzcyI6NDp7czoyOiJpZCI7czozNjoiMmM3ZDJlNzMtYWYzNy05YThiLTAwNDQtNWUxNTA0YjNmYTY1IjtzOjQ6Im5hbWUiO3M6NzoiTnVtaW51cyI7czo0OiJ3cGlkIjtzOjk6IjEwMTU0OTY2NCI7czozOiJ1cmwiO3M6MDoiIjt9"/><input class="form-control" id="FirstName" name="first_name" placeholder="First Name" required="" type="text" value=""/><input class="form-control" id="LastName" name="last_name" placeholder="Last Name" required="" type="text" value=""/><input class="form-control" id="email" name="email" placeholder="Email" required="" type="email" value=""/><input class="form-control" id="phone" name="user_phone" pattern="[\+\s0-9]{3,15}" placeholder="Phone" title="Telephone number. Only digits and space signs are allowed" type="tel" value=""/></div>
<div class="form-column right">
<div class="extra-input">
<input id="AccreditedInvestor" name="accredited_investor" type="checkbox"/><label class="checkbox-label" for="AccreditedInvestor">
Include me in the <b>Accredited Investor</b> email list
<span class="help">
<i aria-hidden="true" class="fa fa-question-circle"></i>
<div class="help-box bigger">
Some investment opportunities are limited to accredited investors. Whether you are an accredited investor or not depends on where you live and other criteria. For full details go to https://investingnews.com/accredited-investor-definition/ or search for "accredited investor" in the search bar above.
</div>
</span>
</label>
</div>
<div class="more">
<input class="btn btn-primary" type="submit" value="Get More information"/></div>
<p class="legend">By completing this form, you are giving consent to receive communication from Numinus using the contact information you provide. And remember you can unsubscribe at any time.</p>
</div>
</form>
</div>
Keep reading...
Show less
Cresco Labs to Report Fourth Quarter and Full Year 2020 Financial Results on March 25th, 2021
March 04 | 2021
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).
<p> <b> Event: </b> Cresco Labs Fourth Quarter and Fully Year 2020 Earnings Conference Call <br/><b> Date: </b> Thursday March 25 <sup> th </sup> , 2021 <br/><b> Time: </b> 8:30a.m. EDT <br/><b> Webcast: </b> <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__event.on24.com_wcc_r_3056149_468FE49FCFC5DB54F980873D49216945%26d%3DDwMFaQ%26c%3DeuGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM%26r%3D4Mr59KexZFmnnGDuLmxG8RTohNAorUiZ0GPO7pchmPI%26m%3D-bxgb0jbVc-MfIqIDZxMgUsdn4q0QMcIqCYPFz46kuQ%26s%3Dk6qzM0W24ZYurmHM2Ik-RrA4mcdkuOQZ8DQVzaALk88%26e%3D&esheet=52390492&newsitemid=20210304005157&lan=en-US&anchor=Link&index=1&md5=4e982c8bb768287c38140f9d300452b5" rel="nofollow noopener noreferrer" shape="rect" target="_blank"> Link </a> <br/><b> Dial-in: </b> 1-855-9796-654 (US), 1-833-2942-546 (CA), 0800-640-6441 (UK), 44-20-3936-2999 (Int’l) <br/><b> Passcode: </b> 885607 </p>
<p> Archived access to the webcast will be available for one year on the Cresco Labs <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.crescolabs.com%2Finvestors%2Foverview%2Fdefault.aspx&esheet=52390492&newsitemid=20210304005157&lan=en-US&anchor=investor+relations+website.&index=2&md5=53c83358adb5a1d114e88e27b99a4b32" rel="nofollow noopener noreferrer" shape="rect" target="_blank"> investor relations website. </a> </p>
<p> <b> About Cresco Labs </b> </p>
<p> Cresco Labs is one of the largest vertically integrated, multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted brands including Cresco, Remedi, High Supply, Cresco Reserve, Good News, Wonder Wellness, FloraCal Farms and Mindy’s Chef Led Artisanal Edibles created by James Beard Award-winning chef Mindy Segal. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.crescolabs.com%2F&esheet=52390492&newsitemid=20210304005157&lan=en-US&anchor=CrescoLabs.com&index=3&md5=11c257fc46499b628499ba57e858705b" rel="nofollow noopener noreferrer" shape="rect" target="_blank"> CrescoLabs.com </a> . </p>
<p> <b> Forward Looking Statements </b> </p>
<p> This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the company’s Annual Information Form dated April 28, 2020, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco’s shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise. </p>
<p> <img alt="" class="lazy" data-src="https://cts.businesswire.com/ct/CT?id=bwnews&sty=20210304005157r1&sid=quot2&distro=nx&lang=en" data-srcset="" src="https://cts.businesswire.com/ct/CT?id=bwnews&sty=20210304005157r1&sid=quot2&distro=nx&lang=en" srcset=""/><span></span> </p>
<p id="mmgallerylink"> <span id="mmgallerylink-phrase"> View source version on businesswire.com: </span> <span id="mmgallerylink-link"> <a href="https://www.businesswire.com/news/home/20210304005157/en/" rel="nofollow noopener noreferrer" target="_blank"> https://www.businesswire.com/news/home/20210304005157/en/ </a> </span> </p>
<p> <i> Media: </i> <br/> Jason Erkes, Cresco Labs <br/> Chief Communications Officer <br/><a href="mailto:press@crescolabs.com" rel="nofollow noopener noreferrer" shape="rect" target="_blank"> press@crescolabs.com </a> </p>
<p> <i> Investors: </i> <br/> Jake Graves, Cresco Labs <br/> Manager, Investor Relations <br/><a href="mailto:investors@crescolabs.com" rel="nofollow noopener noreferrer" shape="rect" target="_blank"> investors@crescolabs.com </a> </p>
<p> <i> For general Cresco Labs inquiries: </i> <br/> 312-929-0993 <br/><a href="mailto:info@crescolabs.com" rel="nofollow noopener noreferrer" shape="rect" target="_blank"> info@crescolabs.com </a> </p>
</div>
<p>News Provided by Business Wire via QuoteMedia</p>
<p></p><div class="cp-text-ad"><div class="row text-ad-ofie">
<div class="ad-image large-4 medium-4 small-12 columns"><a href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing">
<img alt="Cannabis Free Report Cover" class="hide-for-small-only" src="https://cdn.investingnews.com/app/uploads/2020/05/Profiting-from-Cannabis-Industry-3D.jpg" title="Profiting from the Cannabis Industry"/></a></div>
<div class="ad-copy large-8 medium-8 small-11 columns"><a href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing">
<h2 align="center" class="ofie">Find out what experts say about profiting from the cannabis market in 2021!</h2></a>
<h5 align="center" class="subheadline">Read our FREE 2021 cannabis outlook report!</h5>
<div align="center"><a class="button red radius" href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing"> Give me my free report! </a></div>
</div>
<!-- end large-8 -->
</div></div>
Keep reading...
Show less
Canopy Growth to Participate in BofA Securities Virtual Consumer & Retail Technology Conference on March 11, 2021
March 04 | 2021
Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .
</div>
<p> The presentation will be conducted by live webcast, and will be accessible through the company’s website at <a href="https://c212.net/c/link/?t=0&l=en&o=3085816-1&h=876494789&u=https%3A%2F%2Fwww.canopygrowth.com%2Finvestors%2Finvestor-events%2F&a=https%3A%2F%2Fwww.canopygrowth.com%2Finvestors%2Finvestor-events%2F" rel="nofollow noopener noreferrer" target="_blank"> https://www.canopygrowth.com/investors/investor-events/ </a> . A replay option will be available on the company’s website until <span> September 7, 2021 </span> for those that cannot participate in the live event. </p>
<p> <b> About Canopy Growth Corporation <br/></b> Canopy Growth (TSX:WEED, NASDAQ:CGC) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both <span> Canada </span> and <span> Germany </span> . Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including <span> Canada </span> , <span> the United States </span> , and <span> Europe </span> through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to <span> the United States </span> through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit <a href="https://c212.net/c/link/?t=0&l=en&o=3085816-1&h=3510474729&u=http%3A%2F%2Fwww.canopygrowth.com%2F&a=www.canopygrowth.com" rel="nofollow noopener noreferrer" target="_blank"> www.canopygrowth.com </a> . </p>
<p> <b> Notice Regarding Forward Looking Statements <br/></b> This press release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable U.S. and Canadian securities laws (collectively, “forward-looking statements”), which involve certain known and unknown risks and uncertainties. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use </p>
<p> of such terms and phrases as “intend,” “goal,” “strategy,” “estimate,” “expect,” “project,” “projections,” “forecasts,” “plans,” “seeks,” “anticipates,” “potential,” “proposed,” “will,” “should,” “could,” “would,” “may,” “likely,” “designed to,” “foreseeable future,” “believe,” “scheduled” and other similar expressions. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Forward–looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those forward–looking statements and the forward–looking statements are not guarantees of future performance. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. A discussion of some of the material factors applicable to Canopy Growth Corporation (“Canopy”) can be found under the section entitled “Risk Factors” in Canopy’s Annual Report on Form 10-K for the year ended March 31, 2020, filed with the Securities and Exchange Commission and with applicable Canadian securities regulators, as such factors may be further updated from time to time in its periodic filings with the Securities and Exchange Commission and with applicable Canadian securities regulators, which can be accessed at <a href="https://c212.net/c/link/?t=0&l=en&o=3085816-1&h=2707441983&u=http%3A%2F%2Fwww.sec.gov%2Fedgar&a=www.sec.gov%2Fedgar" rel="nofollow noopener noreferrer" target="_blank"> www.sec.gov/edgar </a> and <a href="https://c212.net/c/link/?t=0&l=en&o=3085816-1&h=762893464&u=http%3A%2F%2Fwww.sedar.com%2F&a=www.sedar.com" rel="nofollow noopener noreferrer" target="_blank"> www.sedar.com </a> , respectively. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in the filings. Any forward–looking statement included in this press release is made as of the date of this press release and, except as required by law, Canopy disclaims any obligation to update or revise any forward– looking statement. Readers are cautioned not to put undue reliance on any forward–looking statement. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. </p>
<div id="DivAssetPlaceHolder2"> </div>
<p id="PURL"> <img alt="Cision" class="lazy" data-src="https://c212.net/c/img/favicon.png?sn=OT98190&sd=2021-03-04" data-srcset="" height="12" src="https://c212.net/c/img/favicon.png?sn=OT98190&sd=2021-03-04" srcset="" title="Cision" width="12"/> View original content to download multimedia: <a href="http://www.prnewswire.com/news-releases/canopy-growth-to-participate-in-bofa-securities-virtual-consumer--retail-technology-conference-on-march-11-2021-301240144.html" id="PRNURL" rel="nofollow noopener noreferrer" target="_blank"> http://www.prnewswire.com/news-releases/canopy-growth-to-participate-in-bofa-securities-virtual-consumer–retail-technology-conference-on-march-11-2021-301240144.html </a> </p>
<p> SOURCE Canopy Growth Corporation </p>
<p> <img alt="" class="lazy" data-src="https://rt.newswire.ca/rt.gif?NewsItemId=C2338&Transmission_Id=202103040730CANADANWCANADAPR_C2338&DateId=20210304" data-srcset="" src="https://rt.newswire.ca/rt.gif?NewsItemId=C2338&Transmission_Id=202103040730CANADANWCANADAPR_C2338&DateId=20210304" srcset=""/></p>
<p> <img alt="Cision" class="lazy" data-src="https://c212.net/c/img/favicon.png?sn=C2338&sd=2021-03-04" data-srcset="" height="12" src="https://c212.net/c/img/favicon.png?sn=C2338&sd=2021-03-04" srcset="" title="Cision" width="12"/> View original content to download multimedia: <a href="http://www.newswire.ca/en/releases/archive/March2021/04/c2338.html" rel="noopener noreferrer" target="_blank"> http://www.newswire.ca/en/releases/archive/March2021/04/c2338.html </a> </p>
</div>
</div>
<p>News Provided by Canada Newswire via QuoteMedia</p>
<p></p><div class="cp-text-ad"><div class="row text-ad-ofie">
<div class="ad-image large-4 medium-4 small-12 columns"><a href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing">
<img alt="Cannabis Free Report Cover" class="hide-for-small-only" src="https://cdn.investingnews.com/app/uploads/2020/05/Profiting-from-Cannabis-Industry-3D.jpg" title="Profiting from the Cannabis Industry"/></a></div>
<div class="ad-copy large-8 medium-8 small-11 columns"><a href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing">
<h2 align="center" class="ofie">Find out what experts say about profiting from the cannabis market in 2021!</h2></a>
<h5 align="center" class="subheadline">Read our FREE 2021 cannabis outlook report!</h5>
<div align="center"><a class="button red radius" href="https://investingnews.com/free-report-online/investing-in-medical-cannabis-and-legal-cannabis-stocks/" id="Type: Outlook, Category: Cannabis Investing"> Give me my free report! </a></div>
</div>
<!-- end large-8 -->
</div></div>
Keep reading...
Show less
Hill Street Obtains Extension for Closing of Private Placement
March 04 | 2021
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.
For more information regarding the Company or the offering, please contact ir@hillstreetbevco.com, or
<p>Lori Senecal, Interim co-CEO, <a href="https://investingnews.com/company-profiles/hill-street-tsxv-beer-cannabis-infused-beverages/">Hill Street Beverage Company</a> Inc., <a href="mailto:lori@hillstreetbevco.com" rel="noopener noreferrer" target="_blank">lori@hillstreetbevco.com</a></p>
<p>Craig Binkley, Interim co-CEO, <a href="https://investingnews.com/company-profiles/hill-street-tsxv-beer-cannabis-infused-beverages/">Hill Street Beverage Company</a> Inc., <a href="mailto:craig@hillstreetbevco.com" rel="noopener noreferrer" target="_blank">craig@hillstreetbevco.com</a>; </p>
<p>Follow Hill Street on Twitter <a href="https://www.newsfilecorp.com/redirect/bq5eirYA1" rel="noopener noreferrer" target="_blank">https://twitter.com/hillstreetbevco</a><br/>and on Facebook <a href="https://www.newsfilecorp.com/redirect/EAPVt0pVv" rel="noopener noreferrer" target="_blank">http://facebook.com/hillstreetbevco</a></p>
<p><b>FORWARD-LOOKING STATEMENTS</b></p>
<p>Statements in this press release may contain forward-looking information. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expects”, and similar expressions. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances, such as future availability of capital on favourable terms, may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release. The Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as required by securities law.</p>
<p><i><b>Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.</b></i></p>
<p id="corporateNewsLogoContainer"><img alt="Corporate Logo" class="lazy" data-src="https://orders.newsfilecorp.com/files/5205/76074_dfe78f12c4c1aa52_logo.jpg" data-srcset="" id="corporateNewsLogo" src="https://orders.newsfilecorp.com/files/5205/76074_dfe78f12c4c1aa52_logo.jpg" srcset=""/></p>
<p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://www.newsfilecorp.com/redirect/xGBksJ1na" rel="noopener noreferrer" target="_blank">https://www.newsfilecorp.com/release/76074</a></p>
<p><img alt="" class="lazy" data-src="https://www.newsfilecorp.com/newsinfo/76074/310" data-srcset="" src="https://www.newsfilecorp.com/newsinfo/76074/310" srcset=""/></p>
</div>
<p>News Provided by Newsfile via QuoteMedia</p>
<p></p><div class="stock-information sidebar-block">
<div class="title">Request an Investor Kit: <h3>Hill Street Beverage Company</h3></div>
<form action="https://investingnews.com" id="subscribe_per_category" method="POST">
<div class="form-column left">
<input name="profiles_only" type="hidden" value="yes"/><input name="subscription_form" type="hidden" value="yes"/><input name="subscribe_company_profile_form" type="hidden" value="1"/><input name="source" type="hidden" value="https://investingnews.com/news/cannabis-investing/hill-street-obtains-extension-for-closing-of-private-placement/"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="form_name" type="hidden" value="subscribe_cprofile_use_posts"/><input class="referrer" name="referral_url" type="hidden" value=""/><input name="cprofiles[]" type="hidden" value="Tzo4OiJzdGRDbGFzcyI6NDp7czoyOiJpZCI7czozNjoiN2Y3Y2M2NzItN2VjOS1iYzdkLTI4ZDEtNWQxZjdiODllMjQ0IjtzOjQ6Im5hbWUiO3M6Mjg6IkhpbGwgU3RyZWV0IEJldmVyYWdlIENvbXBhbnkiO3M6NDoid3BpZCI7czo5OiIxMDE1MTI0NzAiO3M6MzoidXJsIjtzOjA6IiI7fQ=="/><input class="form-control" id="FirstName" name="first_name" placeholder="First Name" required="" type="text" value=""/><input class="form-control" id="LastName" name="last_name" placeholder="Last Name" required="" type="text" value=""/><input class="form-control" id="email" name="email" placeholder="Email" required="" type="email" value=""/><input class="form-control" id="phone" name="user_phone" pattern="[\+\s0-9]{3,15}" placeholder="Phone" title="Telephone number. Only digits and space signs are allowed" type="tel" value=""/></div>
<div class="form-column right">
<div class="extra-input">
<input id="AccreditedInvestor" name="accredited_investor" type="checkbox"/><label class="checkbox-label" for="AccreditedInvestor">
Include me in the <b>Accredited Investor</b> email list
<span class="help">
<i aria-hidden="true" class="fa fa-question-circle"></i>
<div class="help-box bigger">
Some investment opportunities are limited to accredited investors. Whether you are an accredited investor or not depends on where you live and other criteria. For full details go to https://investingnews.com/accredited-investor-definition/ or search for "accredited investor" in the search bar above.
</div>
</span>
</label>
</div>
<div class="more">
<input class="btn btn-primary" type="submit" value="Get More information"/></div>
<p class="legend">By completing this form, you are giving consent to receive communication from Hill Street Beverage Company using the contact information you provide. And remember you can unsubscribe at any time.</p>
</div>
</form>
</div>
Keep reading...
Show less